No clear answer
Immune reconstitution (cladribine, alemtuzumab, aHSCT): reset the immune system for lasting remission in NMOSD
NMOSD · Immune reconstitution (cladribine, alemtuzumab, aHSCT)
Trials have tried this, but none was a controlled phase 2 or 3 trial with a readable result.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 0
- People in controlled trials
- 0
No controlled trial has reported a result yet.
Other linked trials: 1
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Other linked trials: 1
These linked trials do not set the status.
- SCT-NMOStopped, other reason
Phase 1/2 · 2011 · Not randomised
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-27First listed as No clear answer
Related hypotheses
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): reset the immune system for lasting remission in early MS (CIS or RIS)
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): reset the immune system for lasting remission in primary progressive MS
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): reset the immune system for lasting remission in relapsing MS
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): reset the immune system for lasting remission in relapsing and progressive MS
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): reset the immune system for lasting remission in secondary progressive MS
- Immune reconstitution (cladribine, alemtuzumab, aHSCT): reset the immune system for lasting remission in MS (type not specified)
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error